These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29102759)

  • 1. Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders.
    Bruns RF; Mitchell SN; Wafford KA; Harper AJ; Shanks EA; Carter G; O'Neill MJ; Murray TK; Eastwood BJ; Schaus JM; Beck JP; Hao J; Witkin JM; Li X; Chernet E; Katner JS; Wang H; Ryder JW; Masquelin ME; Thompson LK; Love PL; Maren DL; Falcone JF; Menezes MM; Zhang L; Yang CR; Svensson KA
    Neuropharmacology; 2018 Jan; 128():351-365. PubMed ID: 29102759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders.
    Svensson KA; Hao J; Bruns RF
    Adv Pharmacol; 2019; 86():273-305. PubMed ID: 31378255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice.
    Meltzer HY; Rajagopal L; Matrisciano F; Hao J; Svensson KA; Huang M
    Behav Brain Res; 2019 Apr; 361():139-150. PubMed ID: 30521930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis.
    Svensson KA; Heinz BA; Schaus JM; Beck JP; Hao J; Krushinski JH; Reinhard MR; Cohen MP; Hellman SL; Getman BG; Wang X; Menezes MM; Maren DL; Falcone JF; Anderson WH; Wright RA; Morin SM; Knopp KL; Adams BL; Rogovoy B; Okun I; Suter TM; Statnick MA; Gehlert DR; Nelson DL; Lucaites VL; Emkey R; DeLapp NW; Wiernicki TR; Cramer JW; Yang CR; Bruns RF
    J Pharmacol Exp Ther; 2017 Jan; 360(1):117-128. PubMed ID: 27811173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dopamine D1 receptor positive allosteric modulator, DETQ, improves cognition and social interaction in aged mice and enhances cortical and hippocampal acetylcholine efflux.
    Rajagopal L; Huang M; Mahjour S; Ryan C; Elzokaky A; Svensson KA; Meltzer HY
    Behav Brain Res; 2024 Feb; 459():114766. PubMed ID: 38048913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor.
    Wang X; Heinz BA; Qian YW; Carter JH; Gadski RA; Beavers LS; Little SP; Yang CR; Beck JP; Hao J; Schaus JM; Svensson KA; Bruns RF
    Mol Pharmacol; 2018 Oct; 94(4):1232-1245. PubMed ID: 30111649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
    Mango D; Bonito-Oliva A; Ledonne A; Cappellacci L; Petrelli R; Nisticò R; Berretta N; Fisone G; Mercuri NB
    Exp Neurol; 2014 Nov; 261():733-43. PubMed ID: 25173217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
    Suarez LM; Solis O; Aguado C; Lujan R; Moratalla R
    Cereb Cortex; 2016 Oct; 26(11):4253-4264. PubMed ID: 27613437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine D1 receptor agonist SKF-82958 effectively increases eye blinking count in common marmosets.
    Kotani M; Kiyoshi A; Murai T; Nakako T; Matsumoto K; Matsumoto A; Ikejiri M; Ogi Y; Ikeda K
    Behav Brain Res; 2016 Mar; 300():25-30. PubMed ID: 26675887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Perez XA; Zhang D; Bordia T; Quik M
    Mov Disord; 2017 Apr; 32(4):538-548. PubMed ID: 28256010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders.
    Komatsu H; Maruyama M; Yao S; Shinohara T; Sakuma K; Imaichi S; Chikatsu T; Kuniyeda K; Siu FK; Peng LS; Zhuo K; Mun LS; Han TM; Matsumoto Y; Hashimoto T; Miyajima N; Itoh Y; Ogi K; Habata Y; Mori M
    PLoS One; 2014; 9(2):e90134. PubMed ID: 24587241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of main constituents and mechanisms underlying antidepressant-like effects of Xiaochaihutang in mice.
    Zhang K; Wang F; Yang JY; Wang LJ; Pang HH; Su GY; Ma J; Song SJ; Xiong ZL; Wu CF
    J Ethnopharmacol; 2015 Dec; 175():48-57. PubMed ID: 26318746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infralimbic D1 receptor agonist effects on spontaneous novelty exploration and anxiety-like defensive responding in CD-1 mice.
    Wall PM; Blanchard RJ; Markham C; Yang M; Blanchard DC
    Behav Brain Res; 2004 Jun; 152(1):67-79. PubMed ID: 15135970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new knock-in mouse model of l-DOPA-responsive dystonia.
    Rose SJ; Yu XY; Heinzer AK; Harrast P; Fan X; Raike RS; Thompson VB; Pare JF; Weinshenker D; Smith Y; Jinnah HA; Hess EJ
    Brain; 2015 Oct; 138(Pt 10):2987-3002. PubMed ID: 26220941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippocampal and prefrontal dopamine D1/5 receptor involvement in the memory-enhancing effect of reboxetine.
    De Bundel D; Femenía T; DuPont CM; Konradsson-Geuken Å; Feltmann K; Schilström B; Lindskog M
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):2041-51. PubMed ID: 23672849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function.
    Espadas I; Darmopil S; Vergaño-Vera E; Ortiz O; Oliva I; Vicario-Abejón C; Martín ED; Moratalla R
    Neurobiol Dis; 2012 Dec; 48(3):271-81. PubMed ID: 22820144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid anti-depressant and anxiolytic actions following dopamine D1-D2 receptor heteromer inactivation.
    Shen MY; Perreault ML; Bambico FR; Jones-Tabah J; Cheung M; Fan T; Nobrega JN; George SR
    Eur Neuropsychopharmacol; 2015 Dec; 25(12):2437-48. PubMed ID: 26431907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.